This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guppy, A.E. Articles by Rustin, G.J.S. Search for Related Content PubMed PubMed Citation Articles by Guppy, A.E. Articles by Rustin, G.J.S.

CA125 Response: Can it Replace the Traditional Response Criteria in Ovarian Cancer?

Department of Medical Oncology, Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, United Kingdom

Correspondence: G.J.S. Rustin, M.D., Department of Medical Oncology, Mount Vernon Centre for Cancer Treatment, Rickmansworth Road, Northwood, Middlesex HA6 2RN, United Kingdom. Telephone: 01923-844700; Fax: 01923-844840; e-mail: rustin{at}mtvern.co.uk

CA125 is well established as an accurate and reliable means of monitoring response to treatment and confirming relapse in ovarian cancer patients. Its role in follow-up after initial treatment is less certain and the subject of a current clinical trial. Measuring response with computerized tomography scans is futile in the majority of patients, as disease is often nonmeasurable at presentation, e.g., ascites or peritoneal deposits, or all measurable disease has been removed at the time of surgery. Serial changes in CA125 can be used as a reliable indicator of disease response or progression so that patients can be classified as responding or progressing according to either standard or CA125 criteria. These precise definitions are currently being prospectively validated in conjunction with the new response evaluation criteria in solid tumor response guidelines and are being incorporated into all future clinical trials.

Key Words. CA125 • Ovarian cancer • Response criteria

This article has been cited by other articles:

				M Candelaria, D Gallardo-Rincon, C Arce, L Cetina, J. Aguilar-Ponce, O Arrieta, A Gonzalez-Fierro, A Chavez-Blanco, E de la Cruz-Hernandez, M. Camargo, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Ann. Onc., September 1, 2007; 18(9): 1529 - 1538. [Abstract] [Full Text] [PDF]

				G. J. S. Rustin, R. C. Bast Jr., G. J. Kelloff, J. C. Barrett, S. K. Carter, P. D. Nisen, C. C. Sigman, D. R. Parkinson, and R. W. Ruddon Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer Clin. Cancer Res., June 1, 2004; 10(11): 3919 - 3926. [Full Text] [PDF]